Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash 79 tok/s
Gemini 2.5 Pro 49 tok/s Pro
GPT-5 Medium 45 tok/s
GPT-5 High 43 tok/s Pro
GPT-4o 103 tok/s
GPT OSS 120B 475 tok/s Pro
Kimi K2 215 tok/s Pro
2000 character limit reached

Evidence-based diagnostic reasoning with multi-agent copilot for human pathology (2506.20964v1)

Published 26 Jun 2025 in cs.CV and cs.AI

Abstract: Pathology is experiencing rapid digital transformation driven by whole-slide imaging and AI. While deep learning-based computational pathology has achieved notable success, traditional models primarily focus on image analysis without integrating natural language instruction or rich, text-based context. Current multimodal LLMs (MLLMs) in computational pathology face limitations, including insufficient training data, inadequate support and evaluation for multi-image understanding, and a lack of autonomous, diagnostic reasoning capabilities. To address these limitations, we introduce PathChat+, a new MLLM specifically designed for human pathology, trained on over 1 million diverse, pathology-specific instruction samples and nearly 5.5 million question answer turns. Extensive evaluations across diverse pathology benchmarks demonstrated that PathChat+ substantially outperforms the prior PathChat copilot, as well as both state-of-the-art (SOTA) general-purpose and other pathology-specific models. Furthermore, we present SlideSeek, a reasoning-enabled multi-agent AI system leveraging PathChat+ to autonomously evaluate gigapixel whole-slide images (WSIs) through iterative, hierarchical diagnostic reasoning, reaching high accuracy on DDxBench, a challenging open-ended differential diagnosis benchmark, while also capable of generating visually grounded, humanly-interpretable summary reports.

List To Do Tasks Checklist Streamline Icon: https://streamlinehq.com

Collections

Sign up for free to add this paper to one or more collections.

Summary

We haven't generated a summary for this paper yet.

Dice Question Streamline Icon: https://streamlinehq.com

Follow-up Questions

We haven't generated follow-up questions for this paper yet.